Ki-67与传统生物学标志物预测乳腺癌化疗药物敏感性的研究进展

乳腺癌是女性最常见的恶性肿瘤疾病。增殖抗原Ki-67、雌激素受体（ER）、孕激素受体（PR）及人表皮生长因子受体-2（CerbB-2）是乳腺癌病理检测常用生物标记物。多项研究证实,Ki-67高表达的乳腺癌化疗药物敏感性更高。ER、PR目前被广泛用于乳腺癌内分泌治疗的疗效预测,已有研究证实其可作为辅助化疗药物敏感性预测指标。CerbB-2阴性乳腺癌提示化疗敏感性较高已得到初步证实。本文阐述了有关Ki-67与传统生物学标志物预测乳腺癌辅助化疗药物敏感性的研究进展。

The progress of predictive value of Ki-67 and traditional biomarkers for sensitivity to adjuvant chemotherapy in breast cancer

Breast cancer is the most common cancer in women.The proliferation antigen Ki-67,oestrogen receptors（ER） and progesterone receptors（PR） and CerbB-2 are currently used in routine pathological assessment of breast cancer.Several studies have confirmed that over-expression of Ki-67 in breast cancer canpredict higher sensitivity to chemotherapy.ER and PR have their greatest utility in predicting response to hormonal therapy.Some studies have demonstrated thatthey can predict the response to chemotherapy.The absense of CerbB-2 in brea-st cancer has been shown to predict for improved response to chemotherapy.W e review the previous studies on the predictive value of these biomarkers for response to adjuvant chemotherapy in breast cancer.